Literature DB >> 19371576

BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices.

H Jourdi1, L Hamo, T Oka, A Seegan, M Baudry.   

Abstract

Neurotoxicity is involved in various neurodegenerative diseases including Parkinson's disease (PD), which affects mesencephalic dopaminergic neurons of the substantia nigra (SN). Positive alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators (PARMs, a.k.a. Ampakines, such as CX614) increase brain-derived neurotrophic factor (BDNF) protein levels in vivo and in cultured hippocampal slices. BDNF is a survival factor for various neuronal cell types including mesencephalic dopaminergic neurons. Using cultured mesencephalic and hippocampal slices, we investigated whether preincubation with CX614 could provide neuroprotection against MPP(+) toxicity and whether such neuroprotection was mediated by BDNF. Various treatment protocols were tested to demonstrate CX614-induced neuroprotection against MPP(+). Pretreatment with CX614 significantly reduced MPP(+)-induced toxicity and increased BDNF levels in both hippocampal and mesencephalic cultured slices; CX614 pretreatment for 6 h in hippocampal slices and 24 h in mesencephalic slices was sufficient to produce significant neuroprotection as assessed with lactate dehydrogenase release in slice medium and propidium iodide uptake in slices. Both a BDNF scavenger and an inhibitor of the BDNF receptor TrkB, abrogated CX614-mediated reduction of MPP(+)-induced toxicity. Inhibition of Ca(2+)-activated proteases, calpains, was also protective against MPP(+)-induced toxicity. However, co-application of calpain inhibitor with CX614 abolished CX614-mediated protection, suggesting a dual action of calpains in this model. We conclude that CX614 is neuroprotective against MPP(+)-induced toxicity, an effect mediated by increased BDNF expression and activation of BDNF-dependent signaling pathways. Our results provide support for using PARMs as a new therapy for neurodegenerative disorders, including PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371576      PMCID: PMC3659791          DOI: 10.1016/j.neuropharm.2009.01.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  43 in total

1.  The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn.

Authors:  T Hayashi; H Umemori; M Mishina; T Yamamoto
Journal:  Nature       Date:  1999-01-07       Impact factor: 49.962

2.  Stable expression of recombinant AMPA receptor subunits: binding affinities and effects of allosteric modulators.

Authors:  M Hennegriff; A Arai; M Kessler; P Vanderklish; M S Mutneja; G Rogers; R L Neve; G Lynch
Journal:  J Neurochem       Date:  1997-06       Impact factor: 5.372

3.  Enhancement by an ampakine of memory encoding in humans.

Authors:  M Ingvar; J Ambros-Ingerson; M Davis; R Granger; M Kessler; G A Rogers; R S Schehr; G Lynch
Journal:  Exp Neurol       Date:  1997-08       Impact factor: 5.330

Review 4.  MPTP: current concepts and controversies.

Authors:  J W Langston; I Irwin
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

5.  Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system.

Authors:  M B Spina; S P Squinto; J Miller; R M Lindsay; C Hyman
Journal:  J Neurochem       Date:  1992-07       Impact factor: 5.372

6.  Effects of positive AMPA receptor modulators on calpain-mediated spectrin degradation in cultured hippocampal slices.

Authors:  Hussam Jourdi; Ted Yanagihara; Ulises Martinez; Xiaoning Bi; Gary Lynch; Michel Baudry
Journal:  Neurochem Int       Date:  2005-01       Impact factor: 3.921

7.  Developmental changes in calpain activity, GluR1 receptors and in the effect of kainic acid treatment in rat brain.

Authors:  X Bi; J Chen; M Baudry
Journal:  Neuroscience       Date:  1997-12       Impact factor: 3.590

8.  Brain-derived neurotrophic factor signal enhances and maintains the expression of AMPA receptor-associated PDZ proteins in developing cortical neurons.

Authors:  Hussam Jourdi; Yuriko Iwakura; Mako Narisawa-Saito; Kyoko Ibaraki; Huabao Xiong; Masahiko Watanabe; Yasunori Hayashi; Nobuyuki Takei; Hiroyuki Nawa
Journal:  Dev Biol       Date:  2003-11-15       Impact factor: 3.582

9.  Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum.

Authors:  H Okazawa; M Murata; M Watanabe; M Kamei; I Kanazawa
Journal:  FEBS Lett       Date:  1992-11-23       Impact factor: 4.124

10.  Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

Authors:  Michael J O'Neill; Tracey K Murray; Katherine Whalley; Mark A Ward; Caroline A Hicks; Sandra Woodhouse; David J Osborne; Phil Skolnick
Journal:  Eur J Pharmacol       Date:  2004-02-20       Impact factor: 4.432

View more
  22 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 2.  Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration.

Authors:  Michel Baudry; Xiaoning Bi
Journal:  Trends Neurosci       Date:  2016-02-10       Impact factor: 13.837

Review 3.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

4.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

5.  Calpain plays a central role in 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in cerebellar granule neurons.

Authors:  Richard A Harbison; Kristen R Ryan; Heather M Wilkins; Emily K Schroeder; F Alexandra Loucks; Ron J Bouchard; Daniel A Linseman
Journal:  Neurotox Res       Date:  2010-03-24       Impact factor: 3.911

6.  Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone.

Authors:  S Samantaray; V H Knaryan; C Le Gal; S K Ray; N L Banik
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

7.  Firing pattern modulation through SK channel current increase underlies neuronal survival in an organotypic slice model of Parkinson's disease.

Authors:  Yuan Wang; Liang Qu; Xue-Lian Wang; Li Gao; Zhen-Zhen Li; Guo-Dong Gao; Qian Yang
Journal:  Mol Neurobiol       Date:  2014-05-20       Impact factor: 5.590

8.  Distinct roles for μ-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration.

Authors:  Yubin Wang; Victor Briz; Athar Chishti; Xiaoning Bi; Michel Baudry
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

9.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

10.  Adaptive modifications in the calpain/calpastatin system in brain cells after persistent alteration in Ca2+ homeostasis.

Authors:  Roberto Stifanese; Monica Averna; Roberta De Tullio; Marco Pedrazzi; Francesco Beccaria; Franca Salamino; Marco Milanese; Giambattista Bonanno; Sandro Pontremoli; Edon Melloni
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.